肿瘤易感基因检测策略的思考  

Strategies for cancer susceptibility gene testing

作　　者：姜惠琴 郭玮 Jiang Huiqin;Guo Wei(Department of Laboratory Medicine,Zhongshan Hospital,Fudan University,Shanghai200032,China)

机构地区：[1]复旦大学附属中山医院检验科,上海200032

出　　处：《中华检验医学杂志》2024年第11期1237-1241,共5页Chinese Journal of Laboratory Medicine

基　　金：上海市青年科技英才扬帆计划(21YF1440200);国家自然科学基金(82172348)。

摘　　要：为探讨肿瘤易感基因检测的普及所引发的策略层面的争议和思考,该文围绕肿瘤易感基因检测的受检人群、检测基因和组合以及检测方法等,结合最新研究进展、临床实践经验及专家观点,阐述不同策略选择时的考量因素,同时探讨当前肿瘤易感基因检测面临的挑战。肿瘤易感基因检测在肿瘤预防及个体化诊疗方面具有重要意义,然而在临床实践中必须全面考虑各种因素,以推动其良性发展及广泛应用。To explore the controversies and considerations at the strategic level triggered by the popularization of cancer susceptibility gene testing,this article focuses on the testing population,gene panel,and testing methods.By integrating the latest research advances,clinical practice experiences,and expert opinions,it describes the factors to consider when selecting different strategies.Concurrently,the article discusses the current challenges in cancer susceptibility gene testing.While cancer susceptibility gene testing holds significant importance in cancer prevention and individualized treatment,comprehensive consideration of various factors in clinical practice is essential for promoting its beneficial development and broader application.

关 键 词：肿瘤综合征 遗传性 基因检测 易感基因 

分 类 号：R730.4[医药卫生—肿瘤]